Summit Therapeutics Inc.
SMMT
Rank in Stocks
#1685
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering,... Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Share Price
$15.80
Last synced: 2026-10-21
Market Cap
$12.61B
Change (1 day)
-1.78%
Change (1 year)
-17.52%
Country
US
Trade Summit Therapeutics Inc. (SMMT)
Category
Healthcare
Stock price history for Summit Therapeutics Inc. (SMMT)
Highest end of day price: $16.40 on 2026-10-01
Lowest end of day price: $11.32 on 2015-03-01
Lowest end of day price: $11.32 on 2015-03-01
Stock price history of Summit Therapeutics Inc. from 2015 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | -6.35% |
| 2025 | -2.36% |
| 2024 | 648.94% |
| 2023 | -27.28% |
| 2022 | -16.52% |
| 2021 | -23.50% |
| 2020 | 244.19% |
| 2019 | 23.13% |
| 2018 | -88.74% |
| 2017 | 19.67% |
| 2016 | -15.67% |
| 2015 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.00 | 7.59% |
CH
|
